Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Europe. The aim of this observational study is to investigate the efficacy (e.g. glycemic control) and safety (e.g. hypoglycemic episodes) when adding repaglinide to a monotherapy of metformin in type 2 diabetic patients under normal clinical practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Metformin; Repaglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Metformin monotreatment

• HbA1c greater than 7%

• Treatment according to SPC

• Informed consent obtained

Exclusion Criteria:

• Any contraindication to the use of repaglinide (according to the SPC)